MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis | Zendy

Olga Novosad | Zendy; Tetiana Skrypets | Zendy; Yan Pastushenko | Zendy; I. Titorenko | Zendy; Arina Martynchyk | Zendy; O. Skachkova | Zendy; M. Inomistova | Zendy; О. Gorbach | Zendy; N. Khranovska | Zendy; Irina Kryachok | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis

Author(s) -

Olga Novosad,

Tetiana Skrypets,

Yan Pastushenko,

I. Titorenko,

Arina Martynchyk,

O. Skachkova,

M. Inomistova,

О. Gorbach,

N. Khranovska,

Irina Kryachok

Publication year - 2018

Publication title -

klinicka onkologie

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.204

H-Index - 13

eISSN - 1802-5307

pISSN - 0862-495X

DOI - 10.14735/amko2018130

Subject(s) - neuroblastoma ras viral oncogene homolog , kras , langerhans cell histiocytosis , medicine , mapk/erk pathway , mutation , oncology , cancer research , progressive disease , kinase , chemotherapy , cancer , disease , biology , gene , colorectal cancer , biochemistry , microbiology and biotechnology

Clinical outcomes of Langerhans cell histiocytosis (LCH) are highly variable. It has been suggested that mitogen-activated protein kinase (MAPK) /extracellular signal-regulated kinases (ERK) signaling pathway might be activated in LCH patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research